相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- President Trump announced 100% tariffs on all imported branded and patent-protected medicines to the US starting October 1, 2025, unless companies are actively building manufacturing plants in America. - Indian pharmaceutical stocks plummeted up to 5% following the announcement, with Sun Pharma hitting its yearly low and the Nifty Pharma Index declining 2.54%. - The policy could significantly impact Indian pharma companies that generate substantial revenue from US exports, potentially affecting over $233 billion of US pharma imports while exempting generic drug exporters. - Companies may face reduced profits or be forced to invest in expensive US manufacturing facilities to avoid the tariffs and maintain market access.
- Indian Contract Research and Development and Manufacturing Organizations (CRDMOs) are attracting increased attention from global pharmaceutical companies as Big Pharma pursues geographic diversification strategies. - Rising demand for antibody-drug conjugate (ADC)-related CDMO services and future opportunities in GLP-1 diabetes and obesity treatments are positioned as significant growth drivers from 2026. - Key players including Piramal Pharma, Syngene, Laurus Labs, Cohance, and Gland Pharma are strategically positioning for future gains despite current destocking challenges affecting near-term growth. - Gland Pharma is expanding its GLP-1 cartridge fill-finish capacity from 40 million to 140 million units by the end of next year, reflecting the industry's optimistic long-term outlook.
- Piramal Pharma Limited is investing $90 million to expand its facilities in Lexington, Kentucky and Riverview, Michigan, responding to increasing demand for US-based pharmaceutical manufacturing. - The Kentucky site will gain 24,000 square feet of manufacturing space with new filling lines and lyophilizers by late 2027, while the Michigan facility will add commercial-scale capabilities for payload-linkers used in antibody-drug conjugates by end of 2025. - This investment aligns with recent US policy shifts promoting domestic pharmaceutical production, including new tariffs and an executive order to reduce regulatory barriers for drug manufacturing sites.
- OneSource Specialty Pharma expects strong order book growth driven by the global weight-loss drug boom, with semaglutide patent expiring in over 100 countries including India, Canada, and Brazil in early 2026. - The Indian contract manufacturer is investing $100 million to expand drug-device facilities and scale cartridge filling capacity from 40 million to 200 million units over 18-24 months. - The company targets doubling revenue to $400 million over three years, with semaglutide expected to contribute 10-12% of revenue in its first full year and help expand EBITDA margins to 25-27%. - OneSource aims to become a Day 1 launcher for generic GLP-1 therapies, positioning itself as an end-to-end supplier from API procurement to final patient-ready products.
• Antibody-drug conjugates (ADCs) are gaining traction in APAC, marked by significant investments and collaborations, particularly from Chinese companies, signaling strong potential in targeted cancer therapies. • Cell and gene therapies (CGTs) are experiencing a surge in APAC, with China leading in CAR-T clinical trials and approvals, indicating a growing focus on innovative treatments for oncology and other diseases. • Artificial intelligence (AI) is becoming integral in APAC's pharmaceutical sector, enhancing drug discovery, clinical trials, and personalized medicine, with AI-designed drugs nearing regulatory approval. • The APAC region is solidifying its dominance in clinical trials, driven by a large patient population and regulatory reforms, particularly in oncology, attracting both local and global pharmaceutical firms.
